April Japanese price cut a mixed bag of give and take
This article was originally published in Scrip
The official release of Japan's new reimbursement tariff showing the revised prices for individual drugs that will come into effect on 1 April reveals a complex mixture of relative impact for products and companies, although as usual the figures are overwhelmingly negative.
You may also be interested in...
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.